Poniard Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of cancer therapeutics. Our lead product candidate is picoplatin, a new generation platinum-based cancer therapy that has the potential to become a platform product for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications. Picoplatin is a chemotherapeutic designed to treat solid tumors that are resistant to existing platinum-based cancer therapies. Clinical studies in over 1,100 patients to date suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. We have completed a pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in the second-line treatment of patients with small cell lung cancer. This trial did not meet its primary endpoint of overall survival, potentially due to an imbalance in the use of post-study chemotherapy between the picoplatin and best supportive care treatment arms. We also completed Phase 2 trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant (hormone-refractory) prostate cancer and a Phase 1 study evaluating an oral formulation of picoplatin in solid tumors. During 2010, our corporate strategy focused on identifying potential regulatory pathways for picoplatin including the possible submission of a New Drug Application, or NDA, for picoplatin based on our Phase 3
Company profile
Ticker
PARD, PARDP
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Neorx Corp
SEC CIK
Corporate docs
IRS number
911261311
Latest filings (excl ownership)
15-12G
Securities registration termination
2 Apr 12
8-K
Departure of Directors or Certain Officers
2 Apr 12
NT 10-K
Notice of late annual filing
30 Mar 12
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Mar 12
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Mar 12
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Mar 12
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Mar 12
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Mar 12
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Mar 12
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Mar 12
Latest ownership filings